Myelodysplastic Syndromes - MDS
From left to right : Vu H. Duong, M.D., Maria R. Baer, M.D., and Ashkan Emadi, M.D., Ph.D., specialists in the treatment of MDS in the Hematologic Malignancies Program at UMGCCC
The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) has been named a center of excellence for the treatment of myelodysplastic syndromes by the Myelodysplastic Syndromes (MDS) Foundation.
Myelodysplastic Syndromes are a group of bone marrow disorders in which the bone marrow does not produce enough healthy blood cells.
The center of excellence designation recognizes academic cancer centers that have particular expertise in treating patients with MDS, have available cytogenetics and/or molecular genetics resources, have published peer-reviewed publications in the field and offer patients access to clinical research trials investigating new approaches to the prevention, diagnosis and treatment MDS.
"This designation is an endorsement of our cancer centers outstanding clinical program in hematologic malignancies and in the exciting scientific research underway here to improve the lives of patients diagnosed with MDS and other blood cancers, says Kevin J. Cullen, M.D., director of UMGCCC.